The IDH1, ATRX and TP53 combined mutant (IDH1+/ATRX+/TP53+) samples in our glioma cohort presented lower levels of TMEFF2 promoter methylation and higher levels of TMEFF2 expression compared with other samples. The gene discussed is IDH1; the disease is central nervous system cancer.